Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase 3 3Phase 1 3Phase 2 2Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Neoplasms 37Carcinoma, Non-Small-Cell Lung 29Prostatic Neoplasms 20Neoplasm Metastasis 19Breast Neoplasms 19Colorectal Neoplasms 17Squamous Cell Carcinoma of Head and Neck 14Leukemia, Myeloid, Acute 14Stomach Neoplasms 12Ovarian Neoplasms 12Melanoma 12Lung Neoplasms 12Carcinoma, Hepatocellular 12Recurrence 11Hematologic Neoplasms 10Endometrial Neoplasms 10Rectal Neoplasms 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Pancreatic Neoplasms 9Lymphoma 9Head and Neck Neoplasms 9Myasthenia Gravis 8Leukemia 8Urinary Bladder Neoplasms 7Neoplasms by Site 7Neoplasms by Histologic Type 7Lymphoma, Large B-Cell, Diffuse 7Glioblastoma 7Fatigue 6Colonic Neoplasms 6

Interventions

Lisaftoclax 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Leukemia, Promyelocytic, Acute × 1 year × Clear all
NCT07597941 2026-06-04

Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients

The Affiliated People's Hospital of Ningbo University

Phase 2/3 Not yet recruiting
60 enrolled
Other hematologic neoplasm

Leukemia, Promyelocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡